Sector News

Allergan makes appointments to finance leadership team

November 27, 2018
Life sciences

Allergan plc, a leading global biopharmaceutical company, today announced that Daphne Karydas will take on the new role of Senior Vice President Corporate Financial Planning & Analysis and Strategy, and Manisha Narasimhan, PhD, will join the Company as Vice President of Investor Relations and Strategic Initiatives, effective December 10, 2018.

In her new role, Ms. Karydas will continue to work with the Executive Leadership Team to develop and execute the Company’s long-term financial and business strategy. Dr. Narasimhan, who joins Allergan from Regeneron Pharmaceuticals, Inc., will lead the Company’s engagement with the investment community. Both roles will report to Matt Walsh, Executive Vice President and Chief Financial Officer.

“The changes we are announcing today will enable us to further deepen our focus on the corporate strategic and financial planning functions to realize Allergan’s long-term growth potential, while continuing to develop and steward the strong relationships we have established across the financial community,” said Walsh.

Dr. Narasimhan joins Allergan from Regeneron, where she led the Investor Relations function. She has extensive industry experience in the biopharmaceutical sector and well-established relationships within the investment community. Previously, she was an equity research analyst at Canaccord Genuity and Piper Jaffray and has also served as a strategy consultant at Campbell Alliance. Dr. Narasimhan holds a B.Sc. from University of Madras in India and a PhD in Microbiology from New York University.

“We always look to position ourselves to deliver the highest value to patients, customers and shareholders,” said Brent Saunders, Chairman and Chief Executive Officer of Allergan. “A strong financial and strategic planning capability is essential to Allergan’s growth, and Daphne’s leadership in this area will help take us to the next level. With Manisha’s impressive mix of financial and biopharma industry experience, we will continue to build on the solid foundation Daphne set in Investor Relations.”

Ms. Karydas recently served as Senior Vice President Global Investor Relations and Strategy. Before that time, she was a leading institutional investor and financial analyst in the biopharmaceutical sector, joining from J.P. Morgan Asset Management. Ms. Karydas holds a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

Source: Allergan via MarketWatch

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach